NEMLUVIO 30 mg/100mg
nemolizumab-ilto · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Galderma Laboratories, L.P.
NEMLUVIO is a injection, powder, lyophilized, for solution containing nemolizumab-ilto at 30 mg/100mg, taken subcutaneous. Manufactured by Galderma Laboratories, L.P..
Key Facts
- Brand Name
- NEMLUVIO
- Generic Name
- nemolizumab-ilto
- NDC Code (Product)
0299-6220- Manufacturer
- Galderma Laboratories, L.P.
- Strength
- 30 mg/100mg
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761390
- Drug Class
- Interleukin-31 Receptor alpha Antagonist [EPC]
- Marketing Start
- 08/13/2024
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is NEMLUVIO used for?
NEMLUVIO contains nemolizumab-ilto. It is a injection, powder, lyophilized, for solution taken subcutaneous. Consult your doctor for specific uses.
Is NEMLUVIO a controlled substance?
NEMLUVIO is not classified as a controlled substance by the DEA.
What is the generic name for NEMLUVIO?
The generic name for NEMLUVIO is nemolizumab-ilto. There are no other listed brand versions of nemolizumab-ilto.
What is the NDC code for NEMLUVIO 30 mg/100mg?
The NDC (National Drug Code) for NEMLUVIO 30 mg/100mg is 0299-6220, listed by Galderma Laboratories, L.P..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)